FDCDDQ
GTHX

Federation des caisses Desjardins du Quebec’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50
Closed -$153 – 2476
2023
Q4 		$153 Buy
+50
New +$94 ﹤0.01% 2277

Other funds holding GTHX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's GTHX Position: Q1 2024 in Review

Federation des caisses Desjardins du Quebec sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2024, closing a stake of 50 shares — an estimated $153 sold.

Federation des caisses Desjardins du Quebec first reported a position in GTHX in Q4 2023 and held it in 1 quarter. The position peaked at $153 in Q4 2023. 86 funds tracked by Wall St. Rank hold GTHX as of Q1 2024.

  • Federation des caisses Desjardins du Quebec reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Federation des caisses Desjardins du Quebec sold 50 G1 Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $153.
  • Federation des caisses Desjardins du Quebec first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Federation des caisses Desjardins du Quebec's G1 Therapeutics, Inc. Common Stock position peaked at $153 in Q4 2023.
  • 86 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2024, filed 15 May 2024.